Role of the postoperative cholesterol in early al-lograft dysfunction and survival after living do-nor liver transplantation

BACKGROUND:Many studies have confirmed that serum total cholesterol (sTC) concentrations were associated with underlying liver damage and the synthesis capacity of liver. However, the role of postoperative sTC level on evaluating graft function and predicting survival of recipients who un-derwent liver transplantation has not been discussed. METHODS: Clinical data of 231 living donor liver transplan-tation recipients from May 2003 to January 2015 were retro-spectively collected. Patients were stratified into the low sTC group (sTC <1.42 mmol/L, 57 recipients) and high sTC group (sTC ≥1.42 mmol/L, 174 recipients) according the sTC level on postoperative day 3 based on receiver-operating character-istic curve analysis. The clinical characteristics and postoper-ative short- and long-term outcomes were compared between the two groups. RESULTS: Recipients with sTC <1.42 mmol/L experienced more severe preoperative disease conditions, a higher inci-dence of postoperative early allograft dysfunction (38.6% vs 10.3%,P<0.001), 90-day mortality (28.1% vs 10.9%,P=0.002) and severe complications (29.8% vs 17.2%,P=0.041) com-pared to recipients with sTC ≥1.42 mmol/L. Themultivariate analysis demonstrated that sTC <1.42 mmol/L had a 4.08-fold (95% CI: 1.83-9.11,P=0.001) and 2.72-fold (95% CI: 1.23-6.00, P=0.013) greater risk of developing allograft dysfunction and 90-day mortality, and patients with sTC <1.42 mmol/L had poorer overall recipient and graft survival rates at 1-, 3-, and 5-year than those with sTC ≥1.42 mmol/L (67%, 61% and 61%vs 83%, 71% and 69%,P=0.025; 65%, 59% and 59% vs 81%, 68% and 66%,P=0.026, respectively). Cox multivariate anal-ysis showed that sTC <1.42 mmol/L was an independent pre-dicting factor for total recipient survival (HR=2.043; 95% CI:1.173-3.560;P=0.012) and graft survival (HR=1.905; 95% CI:1.115-3.255;P=0.018). CONCLUSIONS: sTC <1.42 mmol/L on postoperative day 3 was an independent risk factor of postoperative early allograftdysfunction, 90-day mortality, recipient and graft survival, which can be used as a marker for predicting postoperative short- and long-term outcomes.